TABLE OF CONTENTS
Volume 1, Issue 4 (July 2004)
Papers |
Case Section |
Case Commentary |
US Legal and Regulatory Update |
EU Legal and Regulatory Update |
Patent Expiry Impact Predictor
Editorial
Editorial: Canada first to pass legislation on delivering generic medicines to developing countries
Jim Keon
J Generic Med 1: 292-294; doi:10.1057/palgrave.jgm.4940034
Papers
Review of the European pharmaceutical legislation
Susan De Stasio and Nadene McClay
J Generic Med 1: 295-304; doi:10.1057/palgrave.jgm.4940035
'Better medicines for children' — Which is the right way forward for Europe?
Nadene McClay
J Generic Med 1: 305-312; doi:10.1057/palgrave.jgm.4940036
If you thought that dawn raids were to do with antitrust ... A critique of the Directive on the Enforcement of Intellectual Property Rights
Veronica Lowe
J Generic Med 1: 313-321; doi:10.1057/palgrave.jgm.4940037
Managed care: US experience and European initiatives
Daniel Simonet
J Generic Med 1: 322-335; doi:10.1057/palgrave.jgm.4940038
Generics companies: Aspiring to innovate
Faiz Kermani
J Generic Med 1: 336-346; doi:10.1057/palgrave.jgm.4940039
Creating brand identity for generic products
Don Williams
J Generic Med 1: 347-352; doi:10.1057/palgrave.jgm.4940040
Case Section
Innovative marketing strategies after patent expiry: The case of GSK's antibiotic Clamoxyl in France
Pierre Chandon
J Generic Med 1: 353-361; doi:10.1057/palgrave.jgm.4940041
Case Commentary
Case Commentary: Innovative marketing strategies after patent expiry
Pierre Chandon, Attila Mándi and Rory W O'Riordan
J Generic Med 1: 362-365; doi:10.1057/palgrave.jgm.4940042
US Legal and Regulatory Update
Salt in the wound — Pfizer's Norvasc patent extended
J Generic Med 1: 366-369; doi:10.1057/palgrave.jgm.4940043
EU Legal and Regulatory Update
EU Legal and Regulatory Update
J Generic Med 1: 370-379; doi:10.1057/palgrave.jgm.4940044
